UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4094) 4094
Book Chapter (15) 15
Newsletter (12) 12
Magazine Article (5) 5
Newspaper Article (3) 3
Conference Proceeding (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3788) 3788
male (2625) 2625
female (2602) 2602
science & technology (2572) 2572
cytarabine - administration & dosage (2548) 2548
life sciences & biomedicine (2544) 2544
middle aged (2143) 2143
adult (2074) 2074
cytarabine - adverse effects (1897) 1897
antineoplastic combined chemotherapy protocols - therapeutic use (1877) 1877
antineoplastic combined chemotherapy protocols - adverse effects (1502) 1502
oncology (1449) 1449
aged (1448) 1448
hematology (1421) 1421
adolescent (1176) 1176
leukemia, myeloid, acute - drug therapy (1096) 1096
cytarabine - therapeutic use (974) 974
treatment outcome (829) 829
cytarabine (813) 813
remission induction (782) 782
chemotherapy (719) 719
child (676) 676
antineoplastic combined chemotherapy protocols - administration & dosage (609) 609
etoposide - administration & dosage (583) 583
abridged index medicus (529) 529
cancer (519) 519
child, preschool (495) 495
daunorubicin - administration & dosage (480) 480
methotrexate - administration & dosage (470) 470
cyclophosphamide - administration & dosage (462) 462
acute myeloid leukemia (448) 448
leukemia (446) 446
combined modality therapy (442) 442
disease-free survival (434) 434
acute disease (429) 429
prognosis (425) 425
recurrence (421) 421
vincristine - administration & dosage (416) 416
drug administration schedule (367) 367
young adult (356) 356
survival rate (342) 342
retrospective studies (340) 340
transplantation (336) 336
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (319) 319
aged, 80 and over (317) 317
doxorubicin - administration & dosage (317) 317
survival analysis (314) 314
methotrexate - adverse effects (307) 307
dose-response relationship, drug (304) 304
leukemia - drug therapy (298) 298
leukemia, myeloid - drug therapy (298) 298
follow-up studies (297) 297
antineoplastic agents - adverse effects (285) 285
infant (285) 285
leukemia, myeloid, acute - mortality (283) 283
mitoxantrone - administration & dosage (275) 275
etoposide - adverse effects (272) 272
medicine & public health (264) 264
antimetabolites, antineoplastic - adverse effects (257) 257
cyclophosphamide - adverse effects (256) 256
daunorubicin - adverse effects (255) 255
idarubicin - administration & dosage (255) 255
prednisone - administration & dosage (255) 255
time factors (244) 244
care and treatment (238) 238
antimetabolites, antineoplastic - administration & dosage (230) 230
vincristine - adverse effects (229) 229
stem cells (228) 228
hematopoietic stem cell transplantation (224) 224
lymphoma, non-hodgkin - drug therapy (224) 224
risk factors (224) 224
animals (223) 223
pharmacology & pharmacy (220) 220
drug therapy, combination (217) 217
transplantation, autologous (217) 217
antineoplastic agents - therapeutic use (213) 213
dexamethasone - administration & dosage (211) 211
prospective studies (201) 201
pediatrics (200) 200
bone marrow transplantation (188) 188
research (183) 183
lymphomas (179) 179
salvage therapy (176) 176
carmustine - administration & dosage (174) 174
dosage and administration (174) 174
cisplatin - administration & dosage (173) 173
drug evaluation (170) 170
immunology (169) 169
injections, spinal (168) 168
patients (166) 166
antineoplastic agents - administration & dosage (165) 165
cytarabine - pharmacology (164) 164
melphalan - administration & dosage (162) 162
antimetabolites, antineoplastic - therapeutic use (161) 161
granulocyte colony-stimulating factor - administration & dosage (161) 161
stem cell transplantation (161) 161
leukemia, lymphoid - drug therapy (160) 160
neutropenia - chemically induced (159) 159
vidarabine - analogs & derivatives (158) 158
leukemia, myeloid, acute - genetics (157) 157
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3837) 3837
Japanese (98) 98
German (71) 71
French (50) 50
Chinese (36) 36
Spanish (34) 34
Russian (19) 19
Polish (17) 17
Italian (11) 11
Czech (6) 6
Portuguese (5) 5
Dutch (3) 3
Norwegian (3) 3
Hungarian (2) 2
Slovak (2) 2
Croatian (1) 1
Romanian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Book Review
The Lancet. Haematology, ISSN 2352-3026, 05/2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Hematology | Science & Technology | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Infections - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced | Index Medicus
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 09/2012, Volume 104, Issue 18, pp. 1386 - 1395
.... Univariate logistic regression was used to estimate the effect of intensity of chemotherapy (treatment arm... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Precursor Cell Lymphoblastic Leukemia-Lymphoma - psychology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Patient Selection | Hydrocortisone - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Time Factors | Attention - drug effects | Vincristine - administration & dosage | Female | Child | Injections, Spinal | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Drug Administration Schedule | Risk Factors | Mercaptopurine - administration & dosage | Mercaptopurine - adverse effects | Logistic Models | Treatment Outcome | Cognition - drug effects | Cranial Irradiation - adverse effects | Remission Induction | Cytarabine - administration & dosage | Intelligence Tests | Methotrexate - adverse effects | Hydrocortisone - adverse effects | Adolescent | Sex Factors | Vincristine - adverse effects | Methotrexate - administration & dosage | Intelligence - drug effects | Care and treatment | Patient outcomes | Acute lymphocytic leukemia | Research | Cognition disorders | Risk factors | Cancer in children | Chemotherapy | Cognition & reasoning | Patients | Leukemia | Children & youth | Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 394 - 401
Summary Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis... 
Burkitt leukaemia | children | chemotherapy | rituximab | Burkitt lymphoma | Rituximab | Chemotherapy | Children | Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Consolidation Chemotherapy | Cytarabine - adverse effects | Genes, myc | Typhlitis - chemically induced | Lymphoma, B-Cell - genetics | Cyclophosphamide - adverse effects | Immunotherapy | Burkitt Lymphoma - genetics | Vincristine - administration & dosage | Female | Maintenance Chemotherapy | Child | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Adolescent | Vincristine - adverse effects | Methotrexate - administration & dosage | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Lymphomas | Leukemia | Central nervous system | Cancer | Index Medicus | Burkitt Leukaemia | Burkitt Lymphoma | adolescents
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2004, Volume 350, Issue 13, pp. 1287 - 1295
Journal Article
British journal of haematology, ISSN 0007-1048, 01/2016, Volume 172, Issue 1, pp. 80 - 88
Summary Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival in younger adults with... 
secondary malignancy | treatment | mantle cell lymphoma | methotrexate | hyper‐CVAD | Secondary malignancy | Treatment | Hyper-CVAD | Methotrexate | Mantle cell lymphoma | Life Sciences & Biomedicine | Hematology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Lymphoma, Mantle-Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Neoplasms, Second Primary - chemically induced | Myelodysplastic Syndromes - chemically induced | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Leukemia, Myeloid, Acute - chemically induced | Doxorubicin - administration & dosage | Rituximab - adverse effects | Dexamethasone - administration & dosage | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Cytarabine - administration & dosage | Rituximab - administration & dosage | Methotrexate - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Methotrexate - administration & dosage | Aged | Doxorubicin - adverse effects | Care and treatment | Chemotherapy | Oncology, Experimental | Clinical trials | Lymphomas | Research | Cancer | Index Medicus | hyper-CVAD
Journal Article